Noninvasive Nasopharyngeal Proteomics Identify Coagulation Abnormalities in SARS-CoV-2

Vaccines/drugs that could utilize the mucosal immune system to produce antibodies in the nose should help stop the coronavirus at the point of entry. Therefore, Identification of biomarkers in nasal microenvironment associated with viral clearance, vaccine implementation, and easily measurable correlates of protection, can allow monitoring of infection-induced immunity and facilitate novel drug/vaccine development. Our study proposes to use mass spectrometry-based proteomics to reflect the host response to COVID-19 infection in the nasopharyngeal environment and to identify any new biomarkers that can be used for designing non-invasive prognostic tools and treatments at the point of entry of the virus.

能够借助黏膜免疫系统在鼻腔内诱导抗体产生的疫苗与药物，可在冠状病毒入侵的初始位点阻断其感染。因此，鉴定鼻腔微环境中与病毒清除、疫苗接种实施以及可便捷量化的保护关联指标相关的生物标志物，能够实现对感染诱导免疫的监测，并推动新型药物与疫苗的研发。本研究拟采用基于质谱的蛋白质组学（mass spectrometry-based proteomics）技术，反映鼻咽微环境中宿主对新型冠状病毒肺炎（COVID-19）感染的应答反应，并鉴定可用于开发病毒入侵初始位点无创预后工具与治疗手段的新型生物标志物。